The DNA damage response comprises DNA repair, cell-cycle checkpoint control, and DNA damage-induced apoptosis that collectively promote genomic integrity and suppress tumorigenesis. Previously, we have shown that the Chk2 kinase functions independently of the Mre11 complex (Mre11, Rad50, and Nbs1) and ATM in apoptosis and suppresses tumorigenesis resulting from hypomorphic alleles of Mre11 or Nbs1. Based on this work, we have proposed that Chk2 limits the oncogenic potential of replicationassociated DNA damage. Here we further address the role of Chk2 and damage-induced apoptosis in suppressing the oncogenic potential of chromosome breaks. We show that loss of Chk2 or a mutation in p53 (R172P), which selectively impairs its function in apoptosis, rescued the lethality of mice lacking Lig4, a ligase required for nonhomologous end-joining (NHEJ) repair of DNA double-strand breaks in G0/G1. In contrast to Lig4 p53 R172P/R172P mice were not prone to organspecific, rapid tumorigenesis. Although the severe NHEJ deficiency of Lig4 −/− was a less potent initiator of tumorigenesis in the p53 R172P/R172P and Chk2 −/− backgrounds, where p53 cell-cycle functions are largely intact, even mild defects in the intra-S and G2/M checkpoints caused by mutations in Nbs1 are sufficient to influence malignancy in p53 R172P/R172P mice. We conclude that the oncogenic potential of double-strand breaks resulting from NHEJ deficiency is highly restricted by nonapoptotic functions of p53, such as the G1/S checkpoint or senescence, suggesting that the particular facets of the DNA damage response required for tumor suppression are dictated by the proliferative status of the tumor-initiating cell.
chromosome instability | kinase signaling | tumor suppressor F ollowing the detection of DNA lesions, the DNA damage response (DDR) coordinates DNA repair, cell-cycle checkpoints, and specialized programs, such as apoptosis and senescence, to prevent genomic instability (1) . DDR genes frequently are mutated in chromosome instability and cancer predisposition syndromes, highlighting the role of the DDR in suppressing malignancy (2) . Markers of DDR activation are observed readily in premalignant lesions, leading to the hypothesis that the DDR is an inducible barrier to tumorigenesis (3) . Indices of DDR activation are reduced as tumors evolve, suggesting that selection against aspects of DNA damage signaling accompany tumor progression (1) .
DNA double-strand breaks (DSBs) are physiologically important lesions, because they can be cytotoxic or cytostatic and generate oncogenic translocations (2, 4) . Two major pathways of DSB repair are used in the cell: nonhomologous end-joining (NHEJ) and homology-directed repair (HDR). The use of HDR is cell cycle dependent, regulated by the activity of cyclin-dependent kinases and, in some cases, by the cell cycle-dependent expression or stability of required factors (5) . HDR preferentially uses the sister chromatid as a template and thus is substantially less error-prone than NHEJ, which typically results in the deletion or addition of DNA sequences at the junction of repair. Deficiencies in both pathways have been linked to chromosomal instability, DNA damage sensitivity, and cancer predisposition, reflecting the hazards posed by DSBs (1) .
The DDR is initiated by the recognition of DSBs that is mediated primarily by the Mre11 complex, consisting of Mre11, Rad50, and Nbs1. DSB engagement by the Mre11 complex is required for subsequent activation of ATM, an apical kinase in the DDR (2) . ATM and related kinases are estimated to modify more than 700 substrates in response to DNA damage on consensus SQ/TQ sites (6, 7) . Among these substrates are key regulators of cell-cycle checkpoints, DNA repair factors, and proteins that regulate apoptosis and senescence, accounting for the broad physiological impact of DDR functions (8) .
Arguably one of the most important ATM substrates is the tumor suppressor p53. p53 controls the G1/S cell-cycle checkpoint and is required for both apoptosis and senescence in various cellular contexts (9) . Deficiency of p53 results in severe predisposition to lymphoma in the mouse (10, 11) . Mice harboring a separation-of-function mutation in p53, p53
R172P
, in which its apoptotic function is abolished but its influence on the G1/S checkpoint and the induction of senescence remain intact, have been established. The spectrum and kinetics of tumor development in p53 R172P/R172P mice are markedly distinct from those of p53 −/− mice (12) . p53 R172P/R172P mice have a late-onset tumor phenotype, exhibiting lymphomas and a variety of solid tumors, suggesting that senescence and G1/S checkpoint functions delay tumorigenesis in the context of apoptotic deficiency. Consistent with this view, the p53 R172P allele retards the development of lymphomas resulting from Myc overexpression compared with p53 heterozygosity (13) . Together, these data indicate that the apoptotic functions of p53 are not sufficient for its role as a tumor suppressor. p53 functions are activated by DSBs induced in G1 cells, leading to the activation of apoptotic as well as nonapoptotic responses. Lig4 −/− and Xrcc4 −/− mice, which lack key components of the NHEJ machinery, exhibit perinatal lethality and are associated with high levels of DSBs in areas of the brain containing differentiated and largely nondividing cell populations (14, 15) . p53 deficiency rescues the lethality of Lig4 −/− and Xrcc4 −/− mice, but Lig4 −/− p53 −/− and Xrcc4 −/− p53 −/− mice have rapid onset of pro-and pre-B-cell lymphomas as well as medulloblastomas with complete penetrance (16, 17) . These data indicate that defective NHEJ-mediated repair of DSBs arising in G1 cells, such as those induced during antigen-receptor gene assembly and in differentiated CNS components, are highly oncogenic when p53 functions are lost (4) .
Previously, we provided evidence that the Chk2 kinase suppressed the oncogenic potential of DNA replication-associated DNA damage through crosses with mice harboring mutations in Mre11 (Mre11 ATLD1/ATLD1 ) and Nbs1 (Nbs1 ΔB/ΔB ) (18) . This interpretation was based on the fact that those Mre11 complex alleles primarily affect the DDR in the S and G2 phases of the cell cycle and exhibit marked tumor predisposition in the context of Chk2 deficiency (19, 20) . In contrast, Chk2 deficiency did not enhance tumorigenesis in Prkdc Scid mice, in which DSBs induced in G1 cells during antigen-receptor gene assembly are not repaired (18) . These data support the view that Chk2 tumor-suppressive activity may be relevant primarily for DNA damage that arises during S or G2 phase (18) .
In this study, we examine genetic contexts in which defective apoptotic responses resulting from either p53 or Chk2 mutation are juxtaposed with DDR mutations that increase DNA damage in G1, S, or G2/M phases of the cell cycle. G1 DNA damage is enhanced in Lig4 −/− mice. Unlike Lig4 −/− p53 −/− mice, Lig4 −/− Chk2 −/− and Lig4 −/− p53 R172P/R172P mice were not highly prone to the rapid development of lymphoma and medulloblastoma. Together, these outcomes suggest that the oncogenic potential of breaks generated by NHEJ deficiency is restricted by nonapoptotic p53 functions such as senescence or the imposition of the G1/S checkpoint. In contrast, Nbs1
ΔC and Nbs1 ΔB mutations, which impair the intra-S-phase and G2/M checkpoints, enhanced tumorigenesis in p53 R172P/R172P mice. Combined with previous data regarding tumor predisposition in Nbs1
Chk2
−/− mice, these results provide evidence for the tumorsuppressive influence of the intra-S and G2/M checkpoints. Collectively, the data presented indicate that the relative potency of apoptosis or senescence for tumor suppression is dependent on the DNA repair or cell-cycle checkpoint status of cancerinitiating cells.
Results

Nbs1 Mutations Influence Tumorigenesis in p53
R172P/R172P Mice. In p53-deficient mice, the DNA damage-dependent induction of apoptosis, senescence, and the G1/S checkpoint are lost. Because senescence and the G1/S checkpoint are intact in p53 R172P/R172P mice, these animals provide a means to assess the importance of p53-dependent apoptosis for suppressing the oncogenic potential of DNA damage associated with DNA replication (12) . We combined p53 R172P/R172P with two Nbs1 mutants, Nbs1 ΔB and Nbs1 ΔC , which impair the response to DNA damage in S phase. The N terminus of Nbs1 contains a Forkhead-associated (FHA) and tandem Brca1 C-terminal (BRCT) phosphopeptide binding motifs, and the C terminus of Nbs1 contains a conserved domain that contributes to the physical interaction between the Mre11 complex and ATM (2, 21, 22) . The Nbs1
ΔC mutant lacks the Cterminal domain and exhibits an intra-S-phase checkpoint defect, as well as a defect in apoptosis, whereas the Nbs1 ΔB mutant, lacking the FHA and first BRCT domain, is defective in both the intra-S and G2/M checkpoints but is competent for apoptosis (19, 23) .
Relative to p53 R172P/R172P alone, both p53 R172P/R172P Nbs1
ΔC/ΔC and p53 R172P/R172P Nbs1 ΔB/ΔB double mutants exhibited reduced survival, a more rapid onset of tumorigenesis, and alterations in tumor spectrum ( Fig. 1 A-D and Tables S1-S7). These results reveal that the intra-S-phase checkpoint defects associated with Nbs1 ΔC/ΔC decrease the latency of tumorigenesis. The reduction in latency was even more pronounced in Nbs1
mutants than in Nbs1 ΔC/ΔC p53 R172P/R172P mutants, indicating that tumor suppression was impaired to a greater extent by defects in both the intra-S and G2/M checkpoints, present in cells from Nbs1 ΔB/ΔB , than by defects in the intra-S checkpoint alone. We observed a marked increase in chromosome instability in cell cultures ( Fig. 1E and Fig. S1 ) from both Nbs1
R172P/R172P and Nbs1 ΔB/ΔB p53 R172P/R172P animals as compared with single mutants, supporting the interpretation that the intra-S and G2/M checkpoints contribute to tumor suppression by promoting genomic integrity. This outcome is in contrast to the observation that tumors from p53 R172P/R172P animals exhibited normal ploidy and few chromosomal aberrations, further underscoring the contributions of the intra-S and G2/M checkpoints to chromosome stability (12) . The combination of p53 R172P/R172P mice with mutations affecting the Mre11 complex indicated that chromosomal instability associated with intra-S and G2/M checkpoint defects enhances tumorigenesis when apoptosis is impaired. The instability in those mutants is attributable primarily to impaired responses to DNA damage that arises during S phase as a result of DNA replication (24) . Deficiency of DNA ligase 4 (Lig4 −/− ) severely impairs NHEJ, and Lig4 −/− mice die in late embryogenesis. These mice exhibit extensive apoptosis in regions of the developing brain that contain ultimately postmitotic cells, including differentiated neurons (15) . The lethality of Lig4 −/− is rescued by the deletion of p53, and the rescued mice exhibit high-penetrance, early-onset medulloblastomas and B-cell lymphomas that exhibit gene duplications and recurrent translocations (17, 25, 26 mice and assessed the viability and development of the embryonic brain. The viability of Lig4 −/− mice was rescued by Chk2 deficiency and the p53 R172P allele, but Lig4 −/− Nbs1 ΔC/ΔC mice were inviable ( Fig. 2 A and B and Table S8 ).
The degree of rescue in these settings, as inferred from size of the animals and level of CNS apoptosis, was correlated with the relative severity of the apoptotic defects in p53 R172P/R172P and Chk2 −/− mice. (Fig. 2 B-D; in D, subpanels 2 and 8 compared with subpanels 1 and 7). In contrast, gross morphological defects were evident in the brains of Lig4 −/− Chk2 −/− mice (Fig. 2D , subpanels 3 and 4 compared with subpanels 5 and 6). These brains contained limited areas of apoptotic cells, but, overall, Lig4
Chk2
−/− double mutants were much less affected than Lig4 −/− single mutants (Fig. 2D , subpanels 9 and 10 compared with subpanel 7). These results are consistent with data suggesting a role for Chk2 in genotoxic stress-induced checkpoint activation in the brain (27) .
The phenotypic rescue observed in Lig4 −/− p53 R172P/R172P and Lig4 −/− Chk2 −/− double mutants was incomplete: Immune system development was not rescued (Fig. 2E) , and both Lig4
−/− and, to a lesser extent, Lig4 −/− p53 R172P/R172P mice exhibited precocious degeneration of the seminiferous tubules (Fig. 2F) . Cumulatively, these data indicate that the embryonic lethality of Lig4 deletion is dependent on apoptosis mediated by Chk2 and p53 and that the myriad pathologies evident are the consequences of impaired NHEJ-mediated DSB repair and the induction of p53-dependent cell-cycle regulatory programs. medulloblastoma with complete penetrance (16, 17 
16). Microscopic analysis identified few lesions in a Lig4
−/− Chk2 −/− cohort, with only 1 of 15 mice exhibiting a granulosa cell tumor (Fig. 3C) . In contrast to a previous report (28) , the tumor spectrum of Lig4 −/− p53 R172P/R172P mice was similar to that of p53 R172P/R172P mice, although the percentage of mice developing tumors was reduced relative to mice with the p53 R172P/R172P mutation alone (Fig. 3 A-C and Table S4 ). The Lig4 −/− p53 R172P/R172P mice that did develop tumors did so more rapidly than did p53 R172P/R172P mice, indicating that defective NHEJ may accelerate tumorigenesis through breakage-induced chromosomal rearrangements. Unlike Lig4 −/− p53 −/− mice, which succumb to tumors before 3 mo of age, Lig4 −/− p53 R172P/R172P mice had a longer median survival of 6.6 mo and developed few lymphomas and no medulloblastomas (Fig. 3C) (16, 17) . Heterozygosity of Lig4, which has been shown to accelerate tumorigenesis in Ink4a/arf −/− mice, did not alter the kinetics of tumor development but altered the tumor spectrum compared with that of p53 R172P/R172P mice (Fig. 3 A-D) (29) . In p53-null backgrounds, it has been reported that loss of NHEJ leads to an increase in chromosomal translocations in both lymphomas and medulloblastomas (25, 26) . We examined chromosomal spreads from primary fibroblasts derived from
Lig4
−/− p53 R172P/R172P embryos to determine if increased genomic instability was evident. We found a marked increase in the number of chromosomal aberrations, particularly fusions and rearrangements, suggesting that a propensity for chromosomal translocations caused by canonical NHEJ deficiency may contribute to tumorigenesis in Lig4 −/− p53 R172P/R172P animals (Fig.  3E ). Together these data indicate that a partial (Chk2 −/− ) or complete (p53 R172P/R172P ) apoptotic defect is sufficient to rescue the lethality of Lig4 deficiency but not to predispose the bearers to early-onset tumors of the CNS or immune system that are observed in the complete absence p53 function. Further, these results demonstrate that the DNA damage-induced activation of nonapoptotic p53-dependent signaling pathways can provoke substantial premature mortality in the absence of tumorigenesis.
Nbs1 and Chk2 Promote Apoptosis in Parallel Pathways. In previous work, we found that ATM and Chk2 independently influence p53-dependent apoptosis, indicated by the observation that the apoptotic defects in Atm −/− and Chk2 −/− mutants were additive. In contrast, Nbs1 ΔC/ΔC was largely epistatic with Atm
, consistent with their functioning in the same pathway (23) . Because loss of Chk2 but not deletion of the C terminus of Nbs1 was sufficient to rescue Lig4 deficiency ( Fig. 2A) , we hypothesized that the Nbs1 in magnitude to that of p53 −/− or p53 R172P/R172P (Fig. 4A) . Correlating with this defect, we observed reduced p53 phosphorylation and stabilization in Nbs1 ΔC/ΔC Chk2 −/− cells compared with either single mutant or wild-type controls (Fig. 4B) . The strong additive phenotype of the Nbs1 ΔC/ΔC Chk2 −/− thymocytes indicated that Nbs1 and Chk2 functioned in parallel pathways and that p53-dependent apoptosis was severely impaired in response to ionizing radiation in these animals.
We compared the apoptotic and cell-cycle checkpoint responses of Nbs1 ΔC/ΔC Chk2 −/− double mutants with those seen with the p53 R172P/R172P mutation, which impairs apoptosis but retains the cell-cycle functions (12) . We found that, like p53
R172P/R172P
, cultures of Nbs1 ΔC/ΔC Chk2 −/− cells had only a minor G1/S defect compared with wild type and a strong defect in ionizing radiationinduced apoptosis in thymocytes (Fig. 4 A and C and Fig. S2 ). As we have reported previously, a normal G1/S response was observed in mouse embryo fibroblasts (MEFs) from Nbs1 ΔC/ΔC (Fig.  4C and Fig. S2 ) (23) . Thus, Nbs1 ΔC/ΔC Chk2 −/− mice phenocopy p53 R172P/R172P mice, exhibiting pronounced apoptotic defects but leaving ionizing radiation-dependent induction of the G1/S cellcycle checkpoint intact.
Nbs1 ΔC/ΔC Chk2 −/− mice did not phenocopy the cancer susceptibility of p53 R172P/R172P animals. p53 R172P/R172P and Nbs1 ΔC/ΔC Chk2 −/− mice were followed over the course of 20 mo (Fig. 4D) . Although tumors arose with a mean latency of ∼11 mo in p53
mice, as previously reported (12), tumorigenesis was not observed in the Nbs1 ΔC/ΔC Chk2 −/− cohort (Fig. 4D) . These data likely indicate that p53 regulation induced by DNA damage is partially intact in Nbs1 ΔC/ΔC Chk2 −/− mice or that the p53 R172P allele blunts the apoptotic response to a broader spectrum of lesions that promote tumorigenesis than the mutations in Nbs1 and Chk2, which are defective primarily in the response to DNA DSBs.
Discussion
With respect to the role of the DDR in tumor suppression, these data shed light on the relationship of apoptosis to cell-cycle regulation, on one hand, and to DSB repair, on the other. In either case, defects in the DNA damage-dependent induction of apoptosis, such as those evident in p53 R172P/R172P and Chk2
mutations, are correlated with increased oncogenic potential. Nonapoptotic DDR signaling outcomes such as activation of the cell-cycle checkpoint mediated by the Mre11 complex and induction of senescence by p53 suppress that potential, as indicated by the fact that individual or combined loss of G1/S, intra-S, and G2/M checkpoint control enhance tumorigenesis in p53
mice (18, 30) . This finding is particularly notable, because tumorigenesis in p53 R172P/R172P mice is enhanced by the loss of p21 and the G1/S checkpoint or by the loss of Nbs1 ΔC/ΔC and the intra-S checkpoint in the absence of major DNA repair defects per se.
DSB repair deficiency also enhances the oncogenic potential of apoptotic defects and appears to do so in a cell cycle-specific manner. This point is starkly illustrated by the observation that NHEJ defects, which are primarily relevant in G0/G1 cells, enhance tumorigenesis most efficiently when the G1/S checkpoint is impaired (e.g., in Lig4 −/− p53 −/− as compared with Lig4 (16) . On the other hand, genetic analysis revealed that Chk2 suppresses tumorigenesis when G2/M checkpoint signaling and repair are defective but not in response to the absence of NHEJ (Fig. 3 and refs. 18 , 31, and 32). The latter result is particularly striking, because it demonstrates that both the severity of the defect in apoptosis and the status of p53-dependent cell-cycle regulation moderate the influence of NHEJ deficiency on tumorigenesis. Hence, depending on the status of p53 signaling, chromosomal breakage arising from defective NHEJ can provoke tumorigenesis, tumorfree premature mortality, or a combination of both outcomes.
Both Nbs1 ΔB and Nbs1 ΔC alleles influence the tumor spectrum of p53 R172P/R172P mutants, but only Nbs1 ΔB promotes tumorigenesis in Chk2 −/− mice, suggesting that particular functions of the Mre11 complex are important when apoptotic defects are less severe. A potential candidate for this activity is DSB resection, the conversion of dsDNA to ssDNA via nuclease activity (33) . In yeast, DSB resection is required for both efficient G2/M checkpoint arrest and HDR, and this process has been proposed to underlie the DSB-induced activation of ATR and Chk1 in mammalian cells (34) (35) (36) . Because the G2/M checkpoint and HDR are defective in Nbs1 ΔB and other alleles that lead to tumorigenesis in mice lacking Chk2 but are intact in Nbs1 ΔC mice, we hypothesize that defects in resection may promote the generation of oncogenic lesions that normally are eliminated by Chk2 activity through apoptosis or additional regulatory functions (18, 31, 37) . Because the cell-cycle checkpoint defects of the Nbs1 In S/G2-phase cells, the activation of apoptosis (indicated in bold) through p53 and Chk2 appears to be the primary mode of suppressing the oncogenic potential of DNA replication-associated DSBs, the levels of which are elevated by mutations in Mre11 or Nbs1 that impair the intra-S and G2/M checkpoints (green type). p53 R172P/R172P mutations. We also cannot rule out the possibility that p53 R172P and Nbs1 ΔC alleles have additional defects in vivo that influence tumor growth. Considering this possibility, and given the diverse tumor spectrum, we predict that these additional functions are unlikely to be tissue specific.
Collectively, these data illustrate the interdependence of DSB repair, cell-cycle checkpoints, and apoptosis in the suppression of malignancy. These results are consistent with a model that in nondividing cells, which are dependent primarily on NHEJ for DSB repair, survival is dependent on apoptosis, but the suppression of oncogenesis relies heavily upon the imposition of cellcycle regulation by p53 (Fig. 4E) . On the other hand, dividing cells experiencing replicative stress and damage at replication forks primarily are dependent on both resection-based checkpoint and repair responses and on apoptosis to suppress the subsequent development of chromosomal instability and oncogenic lesions. Thus, we propose that the DDR barriers that cells must overcome before becoming initiators of tumorigenesis depend on their proliferative status. A more complete mechanistic understanding of the individual processes within the DDR involved in tumor suppression and of their interrelationships will be essential to identify functional biomarkers that will have predictive value in cancer predisposition, progression, and treatment.
Materials and Methods
Flow Cytometry. Thymocytes were isolated from 7-to 9-mo-old animals and exposed ex vivo to the indicated doses of ionizing radiation. Twenty hours after ionizing radiation, cells were stained with Annexin-V FITC and propidium iodide (PI) (Becton Dickinson), and the percentage of double-negative (viable) cells was determined by flow cytometry and normalized to untreated cells (apoptotic ratio).
Checkpoint Analysis. The G1/S checkpoint was assessed in early-passage (< p4) MEFs. Cells were exposed to the indicated doses of ionizing radiation using an X-ray cabinet and 14 h after treatment were pulse labeled with BrdU for 4 h and stained with anti-BrdU-FITC antibodies and PI (Becton Dickinson).
The percentage of S-phase cells was determined by flow cytometry and normalized to untreated cells (S-phase ratio).
Immunohistochemistry. Embryonic day (E) 13.5 embryos or moribund mice were euthanized, fixed in 10% (vol/vol) neutral-buffered formalin, paraffinized, and sectioned using standard methods. Serial sections were stained with H&E or antibodies to cleaved caspase-3 (Millipore). , respectively. Nbs1 ΔB and Nbs1 ΔC mice were described previously (19, 23) . Mice were raised in a pathogen-free facility and genotyped by PCR (details upon request). Mice were maintained on a mixed 129/B6 background and monitored for signs of malignancy or distress three to five times per week. Any animals with palpable tumors or other signs of distress were euthanized and processed for pathological analysis. Appropriate National Institutes of Health guidelines for animal husbandry and treatment were followed.
Western Blotting. Samples were lysed in TNG-150 buffer [50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% Tween-20, 10% (vol/vol) NP40], separated by SDS/ PAGE, and transferred to PVDF membrane (Millipore). Membranes were probed with antibodies for p53 (CM5; Vector), phospho-S15/18 p53 (Cell Signaling), or SMC1 (Abcam). Primary antibodies were detected with appropriate secondary antibodies conjugated to HRP (Jackson) and visualized by ECL (GE).
